Cargando…

Discrimination of approved drugs from experimental drugs by learning methods

BACKGROUND: To assess whether a compound is druglike or not as early as possible is always critical in drug discovery process. There have been many efforts made to create sets of 'rules' or 'filters' which, it is hoped, will help chemists to identify 'drug-like' molecul...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Kailin, Zhu, Ruixin, Li, Yixue, Cao, Zhiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3120701/
https://www.ncbi.nlm.nih.gov/pubmed/21569562
http://dx.doi.org/10.1186/1471-2105-12-157
_version_ 1782206737733910528
author Tang, Kailin
Zhu, Ruixin
Li, Yixue
Cao, Zhiwei
author_facet Tang, Kailin
Zhu, Ruixin
Li, Yixue
Cao, Zhiwei
author_sort Tang, Kailin
collection PubMed
description BACKGROUND: To assess whether a compound is druglike or not as early as possible is always critical in drug discovery process. There have been many efforts made to create sets of 'rules' or 'filters' which, it is hoped, will help chemists to identify 'drug-like' molecules from 'non-drug' molecules. However, among the chemical space of the druglike molecules, the minority will be approved drugs. Classifying approved drugs from experimental drugs may be more helpful to obtain future approved drugs. Therefore, discrimination of approved drugs from experimental ones has been done in this paper by analyzing the compounds in terms of existing drugs features and machine learning methods. RESULTS: Four methodologies were compared by their performance to classify approved drugs from experimental ones. The best results were obtained by SVM, in which the accuracy is 0.7911, the sensitivity is 0.5929, and the specificity is 0.8743. Based on the results, consensus model was developed to effectively discriminate drugs, which further pushed the correct classification rate up to 0.8517, sensitivity up to 0.7242, specificity up to 0.9352. The applications on the Traditional Chinese Medicine Ingredients Database (TCM-ID) tested the methods. Therefore this model has been proven to be a potent tool for identifying drug molecules. CONCLUSION: The studies would have potential applications in the research of combinatorial library design and virtual high throughput screening for drug discovery.
format Online
Article
Text
id pubmed-3120701
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31207012011-06-23 Discrimination of approved drugs from experimental drugs by learning methods Tang, Kailin Zhu, Ruixin Li, Yixue Cao, Zhiwei BMC Bioinformatics Research Article BACKGROUND: To assess whether a compound is druglike or not as early as possible is always critical in drug discovery process. There have been many efforts made to create sets of 'rules' or 'filters' which, it is hoped, will help chemists to identify 'drug-like' molecules from 'non-drug' molecules. However, among the chemical space of the druglike molecules, the minority will be approved drugs. Classifying approved drugs from experimental drugs may be more helpful to obtain future approved drugs. Therefore, discrimination of approved drugs from experimental ones has been done in this paper by analyzing the compounds in terms of existing drugs features and machine learning methods. RESULTS: Four methodologies were compared by their performance to classify approved drugs from experimental ones. The best results were obtained by SVM, in which the accuracy is 0.7911, the sensitivity is 0.5929, and the specificity is 0.8743. Based on the results, consensus model was developed to effectively discriminate drugs, which further pushed the correct classification rate up to 0.8517, sensitivity up to 0.7242, specificity up to 0.9352. The applications on the Traditional Chinese Medicine Ingredients Database (TCM-ID) tested the methods. Therefore this model has been proven to be a potent tool for identifying drug molecules. CONCLUSION: The studies would have potential applications in the research of combinatorial library design and virtual high throughput screening for drug discovery. BioMed Central 2011-05-14 /pmc/articles/PMC3120701/ /pubmed/21569562 http://dx.doi.org/10.1186/1471-2105-12-157 Text en Copyright ©2011 Tang et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tang, Kailin
Zhu, Ruixin
Li, Yixue
Cao, Zhiwei
Discrimination of approved drugs from experimental drugs by learning methods
title Discrimination of approved drugs from experimental drugs by learning methods
title_full Discrimination of approved drugs from experimental drugs by learning methods
title_fullStr Discrimination of approved drugs from experimental drugs by learning methods
title_full_unstemmed Discrimination of approved drugs from experimental drugs by learning methods
title_short Discrimination of approved drugs from experimental drugs by learning methods
title_sort discrimination of approved drugs from experimental drugs by learning methods
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3120701/
https://www.ncbi.nlm.nih.gov/pubmed/21569562
http://dx.doi.org/10.1186/1471-2105-12-157
work_keys_str_mv AT tangkailin discriminationofapproveddrugsfromexperimentaldrugsbylearningmethods
AT zhuruixin discriminationofapproveddrugsfromexperimentaldrugsbylearningmethods
AT liyixue discriminationofapproveddrugsfromexperimentaldrugsbylearningmethods
AT caozhiwei discriminationofapproveddrugsfromexperimentaldrugsbylearningmethods